Organto Foods Stock Price, News & Analysis

Organto Foods (OTC:OGOFF) has appointed Javier Reyes de la Campa as Co-Chair of the Board of Directors, joining Steve Bromley in this leadership role. Reyes de la Campa, a Harvard Business School alumnus with over 25 years of experience in investing and company building, previously served on Organto's Board from 2015 to 2020.

The company has also granted 125,000 stock options to employees at an exercise price of $0.54 per share with a five-year term, and 1,000,000 restricted stock units to directors with a three-year term. The appointment comes as Organto focuses on accelerating growth and expanding its organic food product offerings.

Organto Foods (OTC:OGOFF) has completed the issuance of 4,380,000 common shares to Jaluca Limited at a deemed price of $0.10 per share. The shares were issued as compensation for Jaluca's corporate finance advisory services in the company's debt restructuring and convertible debentures settlement.

Additionally, the company disclosed details about its 2024 bonus program, with total bonuses of $822,000 to be paid to officers and key personnel. The bonus structure includes 70% in equity ($575,400) and 30% in cash ($246,600), with the equity portion already achieved in 2025 but not yet paid.

Organto Foods (OTC:OGOFF) has successfully closed a C$1.0 million private placement with a strategic investor. The company issued 4,000,000 units at $0.25 per unit, with each unit comprising one common share and one-half warrant.

Each whole warrant allows the purchase of one additional common share at $0.35 until December 26, 2026. The proceeds will be used for general working capital. A finder's fee of $60,000 was paid in connection with the placement. The securities are subject to a hold period until October 27, 2025.

Organto Foods (OTC:OGOFF) held its annual general meeting with strong shareholder participation, as 65,975,601 common shares representing approximately 57.9% of eligible outstanding shares were voted. All matters received over 99% support.

Shareholders elected five directors: Steve Bromley, Peter Damouni, Peter Gianulis, Alejandro Maldonado and Joe Riz. The meeting also approved the appointment of Dale Matheson Carr-Hilton Labonte LLP as the company's independent auditor and approved the continuation of Share Option and Restricted Share Unit Plans.

Organto Foods has completed the settlement of its C$8.05 million convertible debentures due November 2026 by issuing 40.25 million common shares at $0.20 per share. The Settlement Shares will be released over 30 months starting June 11, 2025, with 25% released every 3 months from month 21. Following this settlement, Organto's outstanding debt is reduced to approximately C$2.6 million. The company recently completed a $5.3 million private placement and reported record Q1 2025 results. As part of the restructuring, Jaluca Limited will receive 4.38 million common shares at $0.10 per share as an advisory fee, subject to TSX Venture Exchange and shareholder approval.

Organto Foods (OGOFF) has announced a non-brokered private placement to raise C$1.0M through the issuance of 4,000,000 units at C$0.25 per unit. Each unit includes one common share and one-half warrant, with each full warrant exercisable at C$0.35 for 18 months. The company reported strong Q1 2025 performance with 193.5% sales growth, 298.1% gross profit growth, lowest operating costs ratio, and first positive EBITDA. The funds will be used for general working capital, with potential participation from directors and officers. The placement requires TSX Venture Exchange approval and includes a four-month hold period. CEO Steve Bromley attributes the improved performance to extensive restructuring and strategic realignment over the past 18 months.

Organto Foods (OGOFF) reported record-breaking Q1 2025 financial results, marking significant growth and operational improvements. Sales reached $13.6 million, up 193.5% year-over-year, representing 66% of total fiscal 2024 sales. Gross profit increased by 298.1% to $1.1 million. The company achieved its first-ever positive EBITDA of $0.3 million, while cash operating expenses decreased to 6.8% of sales from 10.5% in the prior year. The company reported income from operations of $0.1 million, compared to a loss of $0.3 million in the previous year. These improvements resulted from extensive restructuring and strategic realignment over the past 18 months, including streamlined product portfolio and enhanced go-to-market strategies. The company also announced the grant of 1.4 million stock options to directors, officers, and employees at $0.35 per share, expiring May 27, 2030.

Organto Foods (OGOFF) has secured approval from debentureholders to settle its $8.05 million convertible unsecured subordinated debentures through the issuance of 40.25 million common shares at $0.20 per share. The debentures, originally due November 30, 2026, with an 8% interest rate, received 68.89% approval from holders, exceeding the required 66.7% threshold.

The settlement shares will be subject to a 30-month staged release restriction, with 25% portions being released at 21, 24, 27, and 30 months following issuance. The completion of this debt-to-equity conversion remains subject to TSX Venture Exchange approval.

Organto Foods (OGOFF) reported its fiscal 2024 financial results, showing significant growth with sales reaching $20.7 million, a 48% increase from the previous year's $14.0 million. The company's fourth quarter demonstrated strong momentum with sales of $6.5 million, up 107% year-over-year.

The company achieved a gross profit of $1.8 million (8.5% margin) for the full year, and $0.6 million (9.1% margin) in Q4. Notable events include the sale of three operating subsidiaries in June 2024, resulting in a $2.6 million gain. The company reported a net loss of $2.0 million for 2024, significantly improved from the $13.4 million loss in 2023.

The restructuring efforts included streamlining the product portfolio, refocusing market strategies, and reducing costs through internal reorganization. The company completed a private placement and shares for debt settlements, with convertible debentures expected to convert to equity.